Launch of the TRANSCRIPT study
“Towards a better therapeutic option to reduce relapse in T-cell lymphoma”
Lymphomas are cancers of the lymphatic system and represent the most common hematological malignancy. T-cell lymphomas have been found to account for 15% of adult lymphomas.
Currently, there are two treatment modalities (in case of complete response). The first one involves patients’ monitoring, the second one requires consolidation by hematopoietic stem cells auto transplantation
The objective of the TRANSCRIPT study is to know if autotransplantation reduces relapses of the disease.
Prof. Emmanuel Bachy, Hematologist at the Lyon Sud Hospital and Vice President of the LYSA Scientific Council, gives us an overview of the project:
Overall, sixty hospitals are involved in this study, including fifty in France and ten in Belgium.
Moreover, France welcomed its first patient in August 2022.
The study consists of comparing two therapeutic strategies for the treatment of T-cell lymphoma. The trial concerns patients from 18 to 69 years old.
Patients will be randomly assigned to one of two treatment groups: induction chemotherapy alone (Group A) or induction chemotherapy followed by consolidation with autotransplantation (Group B).
A total of two hundred and four patients will be included in the study over a period of approximately three years. The treatment phase will last approximately nine months and the follow-up of each patient will last at least two years. The TRANSCRIPT study should therefore end in 2028.
A €1.3M grant was allocated for this trial, financed by the French Ministry of Health and Solidarity and managed by the French National Cancer Institute.
The TRANSCRIPT project illustrates the strengthening of collaborative relationships through joint coordination within an academic project, promoted respectively by the HCL in France and the LYSARC in Belgium.
Click here to discover the press release of the TRANSCRIPT study launch